X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2307) 2307
Dissertation (14) 14
Book Chapter (13) 13
Conference Proceeding (2) 2
Magazine Article (2) 2
Book Review (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
fty720 (1857) 1857
animals (988) 988
humans (889) 889
sphingosine - analogs & derivatives (817) 817
fingolimod hydrochloride (627) 627
mice (569) 569
multiple sclerosis (541) 541
sphingosine 1-phosphate (532) 532
sphingosine-1-phosphate (501) 501
fingolimod (494) 494
male (484) 484
female (383) 383
sphingosine (383) 383
propylene glycols - pharmacology (366) 366
pharmacology & pharmacy (360) 360
immunology (356) 356
sphingosine - pharmacology (352) 352
immunosuppressive agents - pharmacology (328) 328
rats (311) 311
immunosuppressive agents - therapeutic use (298) 298
oral fingolimod (295) 295
neurosciences (282) 282
phosphates (271) 271
apoptosis (260) 260
receptors, lysosphingolipid - metabolism (259) 259
multiple-sclerosis (240) 240
inflammation (238) 238
propylene glycols - therapeutic use (235) 235
mice, inbred c57bl (233) 233
biochemistry & molecular biology (232) 232
lymphocyte egress (232) 232
clinical neurology (231) 231
lymphocytes (221) 221
activation (213) 213
cell biology (203) 203
sphingosine - therapeutic use (203) 203
disease models, animal (200) 200
sphingosine - metabolism (196) 196
expression (194) 194
analysis (193) 193
s1p (189) 189
adult (179) 179
lysophospholipids - metabolism (175) 175
experimental autoimmune encephalomyelitis (173) 173
transplantation (169) 169
multiple sclerosis - drug therapy (168) 168
phosphorylation (160) 160
immunosuppressant (158) 158
chemistry, medicinal (156) 156
middle aged (152) 152
fingolimod fty720 (150) 150
fingolimod hydrochloride - pharmacology (150) 150
receptors, lysosphingolipid - agonists (150) 150
research (149) 149
lipids (148) 148
signal transduction (148) 148
t-cells (148) 148
in-vivo (142) 142
cells (138) 138
cancer (137) 137
central-nervous-system (136) 136
relapsing multiple-sclerosis (136) 136
neurology (129) 129
cells, cultured (127) 127
receptors (125) 125
fingolimod hydrochloride - therapeutic use (122) 122
sphingosine kinase (121) 121
kinases (120) 120
sphingosine 1-phosphate receptor (119) 119
rodents (118) 118
dose-response relationship, drug (116) 116
oncology (115) 115
hemic and lymphatic diseases (110) 110
health aspects (109) 109
sphingosine 1-phosphate receptors (109) 109
signal transduction - drug effects (108) 108
circulating mature lymphocytes (106) 106
treatment outcome (105) 105
immunosuppressive agents - administration & dosage (102) 102
t cells (102) 102
drug therapy (101) 101
multidisciplinary sciences (101) 101
phosphotransferases - metabolism (101) 101
propylene glycols - administration & dosage (101) 101
receptor (101) 101
care and treatment (99) 99
apoptosis - drug effects (98) 98
disease (98) 98
inhibition (98) 98
cell line, tumor (96) 96
proteins (96) 96
chemistry, organic (95) 95
multiple sclerosis, relapsing-remitting - drug therapy (94) 94
protein-coupled receptor (94) 94
flow cytometry (93) 93
lymphocytes t (92) 92
physiological aspects (92) 92
administration, oral (91) 91
immunosuppressive agents - adverse effects (91) 91
gene expression (90) 90
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2172) 2172
Chinese (109) 109
Japanese (41) 41
German (27) 27
French (7) 7
Spanish (6) 6
Hungarian (3) 3
Russian (3) 3
Portuguese (2) 2
Korean (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Biology & Therapy, ISSN 1538-4047, 05/2015, Volume 16, Issue 5, pp. 733 - 742
Journal Article
Synthesis, ISSN 0039-7881, 03/2018, Volume 50, Issue 5, pp. 968 - 983
Abstract FTY720 {fingolimod hydrochloride, 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride}, a novel immunosuppressant, was discovered by... 
short review | analogues | immunosuppressant | FTY720 | multiple sclerosis | medicinal chemistry | fingolimod hydrochloride | DRUG | CONVENIENT ACCESS | MECHANISM | ANALOGS | IMMUNOMODULATORY AGENT FTY720 | EFFICIENT SYNTHESIS | CHEMISTRY, ORGANIC | FINGOLIMOD FTY720 | DISCOVERY | CYTOKINE PRODUCTION | BIOLOGICAL EVALUATION
Journal Article
The Journal of pharmacology and experimental therapeutics, ISSN 0022-3565, 08/2016, Volume 358, Issue 2, pp. 359 - 370
Journal Article
Journal Article
PloS one, ISSN 1932-6203, 10/2015, Volume 10, Issue 10, p. e0141781
Sphingosine-1-phosphate receptor 1 (S1P1) mediated regulation of lymphocyte egress from lymphoid organs is recognized as the mechanism of FTY720 (Fingolimod,... 
DEMYELINATING DISEASES | SIGNAL-TRANSDUCTION | SPHINGOSINE 1-PHOSPHATE RECEPTORS | MODULATOR FTY720 | T-CELL SUBSETS | ORAL FINGOLIMOD FTY720 | MULTIDISCIPLINARY SCIENCES | PROTEIN-COUPLED RECEPTORS | CENTRAL-NERVOUS-SYSTEM | LYMPHOCYTE EGRESS | IMMUNOMODULATORY DRUG FTY720 | T-Lymphocyte Subsets - immunology | Fingolimod Hydrochloride - pharmacology | Cricetulus | Encephalomyelitis, Autoimmune, Experimental - metabolism | Capillary Permeability - drug effects | Encephalomyelitis, Autoimmune, Experimental - immunology | Extracellular Signal-Regulated MAP Kinases - metabolism | Heart Rate - drug effects | Proteolysis | Female | Cell Membrane - metabolism | Proto-Oncogene Proteins c-akt - metabolism | CHO Cells | Disease Models, Animal | Fingolimod Hydrochloride - administration & dosage | Multiple Sclerosis - metabolism | Cytokines - metabolism | Encephalomyelitis, Autoimmune, Experimental - drug therapy | Rats | Animals | T-Lymphocyte Subsets - metabolism | Lymphocyte Count | Multiple Sclerosis - immunology | Receptors, Lysosphingolipid - agonists | Multiple Sclerosis - drug therapy | Drugs | Cell culture | Pediatrics | Cardiac arrhythmia | Multiple sclerosis | Intracellular signalling | AKT protein | Nervous system | Egress | Kinases | Leaks | Sphingosine 1-phosphate | Proteins | Ubiquitination | Lymphocytes | Rodents | Medical research | Encephalitis | Sphingosine kinase | Effectiveness | Immunomodulation | Oral administration | Organs | FDA approval | Experimental allergic encephalomyelitis | Medicine | Heart rate | Pathology | Side effects | Bradycardia | Lymphopenia | Lungs | FTY720 | Autoimmune diseases | Laboratory animals
Journal Article
Pain (Amsterdam), ISSN 0304-3959, 2017, Volume 158, Issue 9, pp. 1733 - 1742
Metastatic bone pain is the single most common form of cancer pain and persists as a result of peripheral and central inflammatory, as well as neuropathic... 
TASP0277308 | FTY720 | IL-10 | S1PR1 antagonists | FINGOLIMOD FTY720 | ASTROCYTES IN-VITRO | NEUROSCIENCES | SENSORY NEURONS | CLINICAL NEUROLOGY | BREAST-CANCER | SPHINGOSINE 1-PHOSPHATE RECEPTOR | THERAPY | MULTIPLE-SCLEROSIS | ANESTHESIOLOGY | GROWTH-FACTOR | EXPRESSION | INDUCED NEUROPATHIC PAIN
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 11/2009, Volume 158, Issue 5, pp. 1173 - 1182
FTY720 (fingolimod) is a first-in-class sphingosine 1-phosphate (S1P) receptor modulator that was highly effective in Phase II clinical trials for Multiple... 
Multiple Sclerosis | infection | FTY720 (fingolimod) | S1P (sphingosine 1-phosphate) | autoimmunity | immunotherapy | central nervous system | S1P (sphingosine 1‐phosphate) | Autoimmunity | Infection | Multiple sclerosis | Immunotherapy | Central nervous system | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | T-CELL SUBSETS | IMMUNOMODULATOR FTY720 | PHOSPHORYLATION | AGONISM IMPAIRS | SPHINGOSINE 1-PHOSPHATE RECEPTOR-1 | S1P | ENDOTHELIAL-CELLS | EGRESS | PHARMACOLOGY & PHARMACY | SECONDARY LYMPHOID-TISSUES | T-Lymphocytes - physiology | Phosphorylation | Receptors, Lysosphingolipid - antagonists & inhibitors | Lymph Nodes - pathology | Humans | Astrocytes - pathology | Encephalomyelitis, Autoimmune, Experimental - immunology | Astrocytes - immunology | Propylene Glycols - therapeutic use | Receptors, Lysosphingolipid - genetics | Propylene Glycols - pharmacology | Sphingosine - physiology | Encephalomyelitis, Autoimmune, Experimental - drug therapy | Fingolimod Hydrochloride | Phosphotransferases (Alcohol Group Acceptor) - genetics | Receptors, Lysosphingolipid - physiology | Inflammation - immunology | Lymph Nodes - immunology | Phosphotransferases (Alcohol Group Acceptor) - metabolism | Brain - drug effects | Sphingosine - pharmacology | Sphingosine - analogs & derivatives | Animals | Gap Junctions - physiology | Immune System - drug effects | Multiple Sclerosis - immunology | Sphingosine - therapeutic use | Lysophospholipids - physiology | Multiple Sclerosis - drug therapy | Review
Journal Article
Journal of Neuroimmunology, ISSN 0165-5728, 2014, Volume 270, Issue 1, pp. 13 - 21
Journal Article
Journal of natural products (Washington, D.C.), ISSN 0163-3864, 03/2012, Volume 75, Issue 3, pp. 311 - 335
Journal Article
Scientific reports, ISSN 2045-2322, 2019, Volume 9, Issue 1, pp. 7771 - 13
Mammalian Sphingosine kinase 2 is the primary enzyme responsible for phosphorylating FTY720 to its active form, FTY720-P. Systemic FTY720 treatment confers... 
APOPTOSIS | ORAL FINGOLIMOD | INHIBITION | 1-PHOSPHATE RECEPTOR | PROTEIN-COUPLED RECEPTOR | MULTIDISCIPLINARY SCIENCES | SPHINGOSINE-1-PHOSPHATE | EGRESS | IMMUNOSUPPRESSANT | TYPE-2 | DRUG FTY720 | Phosphorylation | Sphingosine kinase | Cell death | Light | FTY720 | Retina | Photoreceptors | Kinases | Apoptosis
Journal Article
Scientific reports, ISSN 2045-2322, 05/2014, Volume 4, Issue 1, p. 5051
Journal Article